DRG1 Knockout K-562 Polyclonal Cells are a polyclonal knockout cell population generated through CRISPR/Cas9-mediated disruption of the DRG1 gene in the K-562 cell line. This product provides a loss-of-function model to study DRG1-dependent processes in a human hematopoietic cancer background. The polyclonal format preserves population-level heterogeneity, enabling robust functional analyses without clonal selection artifacts.
The K-562 parent line is a BCR-ABL1-positive cell line established from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in blast crisis. K-562 cells serve as a well-characterized model for hematopoietic differentiation, erythroid-like properties, and leukemia cell biology. The line??s dependence on constitutive tyrosine kinase activity from the BCR-ABL1 fusion protein makes it particularly relevant for studying oncogenic signaling and drug resistance mechanisms in CML.
DRG1 encodes a conserved GTPase that functions downstream of mTORC1 and growth factor signaling to couple nutrient and mitogenic cues with ribosome biogenesis and protein translation. DRG1 interacts with the zinc-finger proteins DFRP1 (ZNF593) and DFRP2 (ZNF594), forming complexes that associate with ribosomes and the eIF3 translation initiation complex. Through these interactions, DRG1 promotes the expression of cyclin D1 and other translation initiation factors, while also modulating microtubule dynamics. The mTOR?CS6K axis and transcription factors c-MYC and E2F1 act as key upstream regulators of DRG1 expression, establishing a feed?forward loop that sustains leukemic cell proliferation and survival.
In K-562 cells, DRG1 knockout disrupts the translation of key proliferation drivers, leading to cell cycle arrest and reduced viability. The BCR-ABL1 oncogene may converge on DRG1-dependent ribosome biogenesis to maintain the high protein synthesis rates required for blast crisis phenotypes. This polyclonal knockout model thus enables the dissection of DRG1??s role downstream of BCR-ABL1 and mTOR signaling, providing insights into therapeutic vulnerabilities in CML and other malignancies addicted to enhanced translation.
Typical research applications include functional studies of GTPase-driven regulation of ribosome biogenesis and cell proliferation in leukemia, drug target validation for translation inhibitors, and mechanistic dissection of mTOR-driven oncogenic programs. The polyclonal knockout population can be employed in MTS viability and colony formation assays to assess growth defects, flow cytometry with propidium iodide to monitor cell cycle distribution, western blotting to detect DRG1, cyclin D1, and PARP cleavage, RT-qPCR to quantify MYC and CCND1 transcript levels, puromycin incorporation assays to measure global translation rates, and immunofluorescence to visualize microtubule organization. Researchers are encouraged to contact Ascent Research for additional information or to explore customized experimental applications using this model.
